Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Suzhou Basecare Medical's EBIT per Share for the
six
months ended in Dec. 2025 was HK$-0.40.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.86.
During the past 3 years, the average EBIT per Share Growth Rate was 1.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -25.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Suzhou Basecare Medical's EBIT per Share or its related term are showing as below:
HKSE:02170'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -174.7 Med: -40.3 Max: 1.4
Current: 1.4
During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Suzhou Basecare Medical was 1.40% per year. The lowest was -174.70% per year. And the median was -40.30% per year.
HKSE:02170's 3-Year EBIT Growth Rate is ranked worse than 61.93% of 683
companies
in the Medical Devices & Instruments industry
Industry Median: 9.6
vs HKSE:02170: 1.40
Suzhou Basecare Medical (HKSE:02170) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Suzhou Basecare Medical EBIT per Share Related Terms
Suzhou Basecare Medical EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.86
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suzhou Basecare Medical (HKSE:02170) has a EBIT per Share of HK$-0.86 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Suzhou Basecare Medical and its competitors. According to the industry distribution chart, Suzhou Basecare Medical ranks #423 out of 683 companies in the Medical Devices & Instruments industry, placing it in the top 61.9%.
Is Suzhou Basecare Medical's EBIT per Share too high?
Suzhou Basecare Medical's current EBIT per Share is HK$-0.86. Based on the distribution chart, Suzhou Basecare Medical ranks #423 out of 683 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Suzhou Basecare Medical has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Suzhou Basecare Medical's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Suzhou Basecare Medical ranks #423 out of 683 companies for EBIT per Share. This places Suzhou Basecare Medical in the lower half of its industry. The industry median EBIT per Share is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Suzhou Basecare Medical and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suzhou Basecare Medical's current EBIT per Share is HK$-0.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Basecare Medical stock overvalued right now?
Based on GuruFocus' analysis, Suzhou Basecare Medical (HKSE:02170) is currently considered Possible Value Trap. The stock's GF Value™ is HK$2.94, compared to a current price of HK$1.40 — trading 52.6% below its estimated fair value. The current EBIT per Share is HK$-0.86. Suzhou Basecare Medical's overall GF Score™ is 68/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Suzhou Basecare Medical (HKSE:02170), the current EBIT per Share is HK$-0.86 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Suzhou Basecare Medical (HKSE:02170) Overvalued in 2026?
Based on GuruFocus' analysis, Suzhou Basecare Medical stock appears to be undervalued.
The current stock price of HK$1.40 is trading 52.6% below its estimated GF Value™ of HK$2.94.
GuruFocus considers Suzhou Basecare Medical to be Possible Value Trap.
Key valuation signals for HKSE:02170:
EBIT per Share: HK$-0.86
GF Value™: HK$2.94 vs. price of HK$1.40 (52.6% below fair value)
No single metric tells the full story. See the HKSE:02170 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Suzhou Basecare Medical Corp Ltd is a medical device company based in China, operating in the field of assisted reproduction. It is engaged in the research, development, and provision of medical products and related software in the field of reproductive health, to enable more families to have children. The Group's product portfolio comprises Gems Sperm Wash Gradient Set, Gems Fertilisation Medium, Gavi Instrument, Geri Incubator, Cryostorage System, PGT-A kit, Self sperm testing device, Sperm quality analyser, Genie sequencer, and others. It generates maximum revenue from the sale of testing kits. The Group's reportable segments are: the PRC, which derives maximum revenue, and Australia. Geographically, it operates in the PRC, Europe, Asia (excluding the PRC), and other regions.
68GF Score
Get the complete analysis for HKSE:02170
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02170 has been successfully added to your 
